VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

Rhea-AI Summary

Valion Bio (Nasdaq: VBIO) briefed senior U.S. Department of War and BARDA officials on Entolimod for acute radiation syndrome on May 14, 2026.

Discussion highlighted interest in an oral formulation, dual-tissue radioprotection, prior $35.6M in U.S. government funding, extensive nonclinical and clinical evaluation, and FDA Fast Track, Orphan Drug, and Animal Rule development pathway.

Positive

• Joint May 14 briefing with senior Department of War and BARDA officials
• Approximately $35.6 million in prior non-dilutive U.S. funding
• Over $140 million invested in the Entolimod program to date
• Entolimod evaluated in 42 non-human primate studies
• Approximately 300 human subjects exposed to Entolimod to date
• FDA Fast Track and Orphan Drug designations for acute radiation syndrome

Negative

• Entolimod still in development, advancing toward a future Biologics License Application

News Market Reaction – VBIO

+7.82%

3 alerts

+7.82% Session close to close

-10.7% Trough Tracked

$2.87M Market Cap

0.2x Rel. Volume

In the May 20 session, VBIO gained 7.82%, reflecting a notable positive market reaction. Argus tracked a trough of -10.7% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with a s...

Analysis

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with a steady build-up of U.S. government engagement around Entolimod, including BARDA and NIAID support and over $140 million invested to date. Historically, however, VBIO has often sold off after good news, with several recent positive updates followed by declines. Any outsized move could therefore face mean‑reversion risk, especially given low average liquidity and continuing operating losses of $6.2M last quarter.

Key Figures

Total Entolimod investment: $140 million Non-dilutive funding: $35.6 million Non-human primate studies: 42 studies +5 more

8 metrics

Total Entolimod investment $140 million Cumulative investment in Entolimod program to date

Non-dilutive funding $35.6 million U.S. government funding into Entolimod program

Non-human primate studies 42 studies Entolimod preclinical evaluation

Human subjects approximately 300 Entolimod clinical exposure

Cash balance $7.2M Reported at Q1 2026 results

Operating expenses $5.6M Q1 2026 operating expenses

Net loss $6.2M Q1 2026 net loss

NIAID study funding up to $7 million BLA-enabling in vivo studies for Entolimod

Historical Context

5 past events · Latest: May 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 14	Licensing agreement	Positive	-5.5%	Velocity Bioworks secured exclusive commercial license for BioScan-NMR platform.
May 14	Earnings update	Neutral	-5.5%	Q1 2026 financial results and business update under new identity.
May 11	Earnings date notice	Neutral	+15.6%	Announcement of timing and call details for Q1 2026 results.
May 06	Facility opening	Positive	+2.0%	Opening of Velocity Bioworks biomanufacturing facility for domestic Entolimod production.
May 05	Clinical funding	Positive	-3.4%	NIAID protocol with up to $7M federal funding for BLA-enabling studies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news and funding milestones have frequently been followed by negative price reactions, including on generally positive operational and clinical updates.

Recent Company History

Over the past weeks, Valion Bio has reported several positive operational and government-engagement steps, including a NIAID-funded Entolimod program on May 5 and the grand opening of the Velocity Bioworks facility on May 6. An earnings release and an exclusive NMR platform license on May 14 coincided with share weakness. Today’s cross‑agency Department of War and BARDA briefing on Entolimod extends this pattern of growing U.S. government engagement against a backdrop of a declining share price and low-volume trading.

Key Terms

acute radiation syndrome, toll-like receptor 5, nf-κb signaling, g-csf, +4 more

8 terms

acute radiation syndrome medical

"presented Entolimod for acute radiation syndrome (ARS) to senior officials"

Acute radiation syndrome is the sudden illness that happens after a person absorbs a large dose of ionizing radiation in a short time, damaging blood cells, the gut, skin, and other organs. Think of it like a severe, internal burn that can impair a person’s ability to heal and fight infection. Investors watch it because outbreaks, accidents, or tests can trigger urgent regulatory action, reshape demand for medical treatments and protective equipment, create liability risks, and affect the operations and stock prices of companies in healthcare, energy, insurance, and related supply chains.

toll-like receptor 5 medical

"Entolimod is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-κB"

Toll-like receptor 5 (TLR5) is a protein on certain immune cells that acts like a security sensor, detecting a specific component of bacterial tails and triggering an inflammation and immune response. Investors care because drugs or vaccines that activate or block TLR5 can change how the body fights infections or cancer, serving as therapeutic targets or vaccine ingredients; progress or setbacks in TLR5-focused research can materially affect the value and prospects of biotech firms.

nf-κb signaling medical

"Toll-like receptor 5 (TLR5) agonist that activates NF-κB signaling to stimulate"

NF-κB signaling is a cellular communication pathway that turns on genes controlling inflammation, immune responses and cell survival when tissues face stress or infection; think of it as a switchboard that tells cells how urgently to react. Investors care because overactive or blocked NF-κB can drive diseases (like chronic inflammation and some cancers), making it a common drug target; therapies or safety findings tied to this pathway can materially affect clinical results, regulatory chances and company value.

g-csf medical

"dual-tissue cytoprotection versus single-target G-CSF therapies."

G‑CSF (granulocyte colony-stimulating factor) is a manufactured protein that prompts the bone marrow to produce neutrophils, a type of white blood cell that protects patients from infection after chemotherapy, bone marrow transplant, or severe illness. For investors, G‑CSF products matter because they fulfill a steady, clinical need—like safety gear hospitals must replenish—so changes in approvals, patents, manufacturing capacity, or competing biosimilars can meaningfully affect sales and company valuations.

orphan drug regulatory

"received FDA Fast Track and Orphan Drug designations for Entolimod in"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track regulatory

"received FDA Fast Track and Orphan Drug designations for Entolimod in"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

biologics license application regulatory

"advancing the program toward a Biologics License Application under the FDA's Animal Rule."

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

animal rule regulatory

"toward a Biologics License Application under the FDA's Animal Rule."

A regulatory pathway that allows safety and effectiveness of drugs or vaccines to be judged primarily from well-controlled animal studies when human trials would be unethical or impossible, such as for treatments against rare, lethal exposures. It matters to investors because approval via this route can speed a product to market for urgent or niche needs but carries extra scientific and regulatory risk—think of it as accepting a high-quality dress rehearsal instead of a live show, with requirements for strong animal models and often additional post-approval obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure

SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS) to senior officials from the U.S. Department of War and the Biomedical Advanced Research and Development Authority (BARDA) in a joint briefing held on May 14, 2026. The session was Valion Bio's second engagement with senior Department of War officials, following the Company's April 28, 2026, Pentagon briefing on Entolimod.

We believe the cross-agency engagement reflects continued U.S. government interest in Entolimod as a differentiated medical countermeasure for radiological threats. Agency discussion included a specific interest in an oral formulation of the Company's lead candidate, which would offer operational advantages over injectable agents in mass-casualty scenarios and support broader field deployment for the warfighter. and national stockpile integration.

"This second engagement, requested by the DoW, at senior levels of the Department of War, conducted jointly with BARDA, reflects the increasing interest of Entolimod within the national radiological preparedness conversation," said Michael K. Handley, Chief Executive Officer of Valion Bio. "Cross-agency interest at this level signals that policymakers recognize the strategic importance of a differentiated, dual-tissue radiation countermeasure, and the specific focus on a potential oral formulation underscores the operational realities of field deployment and stockpile readiness that our platform is positioned to address."

Entolimod is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-κB signaling to stimulate bone marrow and protect gastrointestinal tissues following ionizing radiation exposure — a dual-tissue mechanism not available in currently stockpiled countermeasures. Unlike Neupogen® (filgrastim), Neulasta® (pegfilgrastim), and Leukine® (sargramostim), which target hematopoietic recovery alone, Entolimod addresses the gastrointestinal damage that is often the limiting factor for survival at higher radiation doses. Valion Bio is working to advance both injectable and oral transmucosal formulations of Entolimod to support a broad range of deployment scenarios.

The May 14 briefing follows prior Valion Bio engagements with BARDA, the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Company's selection for the Department of War's Tech Watch program. To date, over $140 million has been invested in the Entolimod program, including approximately $35.6 million in non-dilutive U.S. government funding. The compound has been evaluated in 42 non-human primate studies and administered to approximately 300 human subjects, demonstrating a well-characterized safety and efficacy profile.

"The current geopolitical environment continues to elevate radiological preparedness on the national security agenda, and we are seeing that reflected in the depth and frequency of our engagement with U.S. government stakeholders," Mr. Handley continued. "Our objective is straightforward: to ensure that Entolimod — and an oral formulation positioned for mass casualty and warfighter applications — is recognized and supported at the levels required to translate its differentiated profile into deployed national capability."

The Company has received FDA Fast Track and Orphan Drug designations for Entolimod in acute radiation syndrome and is advancing the program toward a Biologics License Application under the FDA's Animal Rule.

Strategic and Competitive Positioning

• Cross-agency convergence: Joint Department of War and BARDA engagement signals coordinated interest across biodefense and biomedical preparedness functions.
• Oral formulation focus: An oral medical countermeasure for ARS would expand operational deployment options for stockpiling, field use, and mass casualty response.
• Differentiated mechanism: TLR5 agonist provides dual-tissue cytoprotection versus single-target G-CSF therapies.
• Regulatory pathway: Animal Rule framework supports development for biodefense applications.
• Government validation: Approximately $35.6 million in prior federal funding and ongoing multi-agency engagement.

About Entolimod for Acute Radiation Syndrome

Entolimod (CBLB502) is a recombinant deletion variant of Salmonella FliC flagellin engineered to activate TLR5 selectively. Upon engagement, Entolimod likely triggers NF-κB-dependent signaling to stimulate G-CSF, PI3K, and IL-6 production, among others, to promote multi-tissue cytoprotection, and inhibit apoptosis in radiosensitive hematopoietic and gastrointestinal tissues. The compound has demonstrated survival benefit as both a radioprotectant and a radiomitigant in controlled non-human primate studies under the FDA's Animal Rule.

About Valion Bio, Inc.

Valion Bio, Inc. (Nasdaq: VBIO), the new corporate identity of Tivic Health Systems, Inc., is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease, and immune dysregulation. The Company's lead candidate, Entolimod for acute radiation syndrome (ARS), has been extensively studied and has demonstrated survival benefits and improved tissue recovery in animal models under the FDA's Animal Rule. Entolimod is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-κB signaling pathways to protect cells from damage and stimulate immune responses. Entolimod for ARS has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist designed for potential broader therapeutic applications, including oncology supportive care. Valion Bio's wholly owned subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that provides biomanufacturing services to third-party biotech companies. Valion Bio also leverages Velocity Bioworks' manufacturing capabilities to advance its own drug pipeline with the expected benefits of lower costs, accelerated manufacturing outcomes, and supply chain security. For more information, visit www.valionbio.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim, "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other U.S. government agencies in Entolimod; the ability of the company to achieve the expected benefits from the acquisition of development and manufacturing assets within expected time frames or at all; changes to the company's relationship with its partners; failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations, including related to the Animal Rule; the company's future development of Entolimod or Entolasta; changes to the company's business strategy; timing and success of pre-clinical and clinical trials and study results; regulatory requirements and pathways for approval; the company's ability to successfully commercialize its product candidates in the future; changes in the markets and industries in which the company does business; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Valion Bio's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.

Investor + Media Contact:

Rich Cockrell
CG Capital
vbio@cg.capital

View original content to download multimedia:https://www.prnewswire.com/news-releases/valion-bio-briefs-senior-department-of-war-and-barda-officials-in-joint-engagement-on-entolimod-for-acute-radiation-syndrome-302776806.html

SOURCE Valion Bio, Inc.

FAQ

What did Valion Bio (NASDAQ: VBIO) announce on May 19, 2026 about Entolimod for acute radiation syndrome?

Valion Bio announced a joint May 14, 2026 briefing to senior Department of War and BARDA officials on Entolimod for acute radiation syndrome. According to Valion Bio, this was its second recent high-level Department of War engagement focused on Entolimod’s potential role in radiological preparedness.

Why is the oral Entolimod formulation important for Valion Bio (VBIO) and acute radiation syndrome preparedness?

The oral Entolimod formulation is viewed as important because it could support field deployment, stockpiling, and mass-casualty response. According to Valion Bio, an oral medical countermeasure may offer operational advantages over injectable agents for warfighters and broader national radiological preparedness scenarios.

How much U.S. government funding has Valion Bio (VBIO) received for Entolimod?

Valion Bio reports approximately $35.6 million in prior non-dilutive U.S. government funding for Entolimod. According to Valion Bio, total investment in the program exceeds $140 million, reflecting multi-agency engagement across BARDA, NIAID, DTRA, and Department of War initiatives including the Tech Watch program.

What preclinical and clinical data support Valion Bio’s Entolimod program for acute radiation syndrome?

Entolimod has been evaluated in 42 non-human primate studies and given to about 300 human subjects. According to Valion Bio, this experience has produced a well-characterized safety and efficacy profile, supporting development as a dual-tissue radioprotective countermeasure under the FDA’s Animal Rule framework.

How does Entolimod differ from existing G-CSF therapies like Neupogen and Neulasta for radiation injury?

Entolimod targets both bone marrow and gastrointestinal protection, unlike G-CSF therapies focused on hematopoietic recovery alone. According to Valion Bio, this dual-tissue approach addresses gastrointestinal damage, which can be the survival-limiting factor at higher radiation doses, potentially differentiating Entolimod in acute radiation syndrome management.

What FDA regulatory designations and pathway support Entolimod’s development for acute radiation syndrome?

Entolimod has received FDA Fast Track and Orphan Drug designations for acute radiation syndrome. According to Valion Bio, the program is advancing toward a Biologics License Application under the FDA’s Animal Rule, a pathway tailored for biodefense products where human efficacy trials are not feasible.